Although a variety of imported ALK-TKIs have been recommended for Chinese patients with advanced ALK-positive NSCLC, their prohibitive costs discourage Chinese patients from using them despite in an urgent need. This evidence concerns the gene ALK and non-small cell lung carcinoma.